Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences
02/26/2021 - 08:00 AM
Seres Therapeutics, Inc. , (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will participate in two upcoming investor conferences:
Cowen 41st Annual Health Care Conference on Tuesday, March 2, 2021. Management will participate in a Microbiome panel discussion as well as 1x1 meetings.
Chardan 3rd Annual Microbiome Medicines Summit on Monday, March 8, 2021. Management will present a corporate overview at 2:30 p.m. ET and participate in 1x1 meetings.
An audio webcast of the Chardan Summit presentation will be available under the “Investors and Media” section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-401 in a Phase 1b study in patients with metastatic melanoma, SER-301 in a Phase 1b study in patients with ulcerative colitis, and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit www.serestherapeutics.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210226005085/en/
MCRB Rankings
#5388 Ranked by Stock Gains
MCRB Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Cambridge
About MCRB
seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.